Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Mesothelioma & Rare Thoracic

Paul Baas

保罗·巴斯

MD, PhD

🏢Netherlands Cancer Institute(荷兰癌症研究所)🌐Netherlands

Professor of Thoracic Oncology胸部肿瘤学教授

52
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Paul Baas at the Netherlands Cancer Institute led the CheckMate 743 trial that established nivolumab plus ipilimumab as a new first-line standard for mesothelioma. He is a key European opinion leader on thoracic malignancies and has contributed extensively to mesothelioma clinical research and guideline development.

Share:

🧪Research Fields 研究领域

Mesothelioma间皮瘤
Immunotherapy免疫治疗
Combination Checkpoint Blockade联合免疫检查点阻断

🎓Key Contributions 主要贡献

Dual Checkpoint Blockade

Led the CheckMate 743 phase III trial demonstrating nivolumab plus ipilimumab superior overall survival versus chemotherapy in first-line pleural mesothelioma.

Photodynamic Therapy

Pioneered intrapleural photodynamic therapy combined with surgery, establishing the Netherlands Cancer Institute as a center of excellence for multimodal mesothelioma treatment.

Guideline Development

Contributed to ESMO and ERS clinical practice guidelines for mesothelioma, translating trial evidence into actionable recommendations for European oncologists.

Representative Works 代表性著作

[1]

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743)

Lancet (2021)

Landmark phase III trial showing dual immunotherapy improved overall survival versus chemotherapy, leading to global regulatory approval for first-line mesothelioma treatment.

[2]

Pemetrexed and cisplatin as first-line chemotherapy for patients with malignant pleural mesothelioma

Journal of Clinical Oncology (2003)

Defined pemetrexed-cisplatin as the chemotherapy standard of care, underpinning two decades of mesothelioma treatment.

[3]

European Respiratory Society guidelines for the management of malignant pleural mesothelioma

European Respiratory Journal (2020)

Comprehensive evidence-based guidelines harmonizing mesothelioma management across European institutions.

🏆Awards & Recognition 奖项与荣誉

🏆Dutch Cancer Society Scientific Award
🏆ESMO Mesothelioma Research Prize
🏆International Mesothelioma Interest Group Lifetime Achievement Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 保罗·巴斯 的研究动态

Follow Paul Baas's research updates

留下邮箱,当我们发布与 Paul Baas(Netherlands Cancer Institute)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment